Nosocomial fungal infections. Old problems and new challenges

Abstract

The frequency of nosocomial mycoses has substantially increased in recent years, primarily because of the use of intensive therapeutic regimens in patients with cancer and organ transplantation. Furthermore, newer fungi previously considered as contaminants or harmless colonizers have now emerged as significant human pathogens, particularly in the immunocompromised host. Only through the collaboration between clinicians, pathologists, microbiologists, and infection control officers can these fungal infections be recognized and treated early. It is hoped that the proper implementation of infection control policies, the advent of newer antifungals and biological response modifiers, and the advances in immunosuppressive regimens for organ transplant recipients will result in a significant improvement in the prevention and treatment of these life-threatening opportunistic mycoses.